{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:01:36Z","timestamp":1785578496064,"version":"3.56.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva (English Edition)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.medine.2026.502443","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:31:34Z","timestamp":1777030294000},"page":"502443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of severe infections by multi-resistant Gram-negative bacteria in critically ill patients"],"prefix":"10.1016","volume":"50","author":[{"given":"Jos\u00e9","family":"Garnacho-Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Adriaensens-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Aldab\u00f3-Pall\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Anaya-Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Andaluz-Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Cant\u00f3n-Bulnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"De Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Fern\u00e1ndez-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Povoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ram\u00edrez-Gallemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Rodr\u00edguez-Oviedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cruz","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medine.2026.502443_bib0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1247804","article-title":"The CARBA-MAP study: national mapping of carbapenemases in Spain (2014-2018)","volume":"14","author":"Gracia-Ahufinger","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.medine.2026.502443_bib0015","unstructured":"Antimicrobial resistance in the EU\/EEA (EARS-Net)\u2014Annual epidemiological report 2023 [Accessed 12 Jun 2025]. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report-2023."},{"key":"10.1016\/j.medine.2026.502443_bib0020","unstructured":"Grupo de Trabajo de Enfermedades Infecciosas y Sepsis, Sociedad Espa\u00f1ola de Medicina Intensiva Cr\u00edtica y Unidades Coronarias. Estudio nacional de vigilancia de infecci\u00f3n nosocomial en servicios de Medicina Intensiva, Informe 2024."},{"key":"10.1016\/j.medine.2026.502443_bib0025","series-title":"WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","year":"2024"},{"key":"10.1016\/j.medine.2026.502443_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","article-title":"Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae","volume":"24","author":"Falcone","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.medine.2026.502443_bib0035","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/cid\/ciad725","article-title":"Clinical features and outcomes of infections caused by metallo-beta-lactamase-producing Enterobacterales: a 3-year prospective study from an endemic area","volume":"78","author":"Falcone","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0040","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s13054-024-05224-3","article-title":"The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts\u2011opinion document","volume":"28","author":"Candel","year":"2024","journal-title":"Critical Care"},{"key":"10.1016\/j.medine.2026.502443_bib0045","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.medin.2022.05.005","article-title":"Antibiotics in development for multiresistant gram-negative bacilli","volume":"46","author":"Rodr\u00edguez","year":"2022","journal-title":"Medicina Intensiva"},{"key":"10.1016\/j.medine.2026.502443_bib0050","doi-asserted-by":"crossref","first-page":"e00135","DOI":"10.1128\/JCM.00135-20","article-title":"Practical comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in adult hospitalized patients with lower respiratory tract infections","volume":"58","author":"Buchan","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.medine.2026.502443_bib0055","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jmii.2024.02.010","article-title":"Application of a multiplex molecular pneumonia panel and real-world impact on antimicrobial stewardship among patients with hospital-acquired and ventilator-associated pneumonia in intensive care units","volume":"57","author":"hen","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.medine.2026.502443_bib0060","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13054-020-03114-y","article-title":"Multicenter evaluation of a syndromic rapid multiplex PCR test for early adaptation of antimicrobial therapy in adult patients with pneumonia","volume":"24","author":"Monard","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.medine.2026.502443_bib0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/antibiotics10010042","article-title":"It\u2019s not easy being green: a narrative review on the microbiology, virulence and therapeutic prospects of multidrug-resistant Pseudomonas aeruginosa","volume":"10","author":"Behzadi","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.medine.2026.502443_bib0070","doi-asserted-by":"crossref","first-page":"dlab092","DOI":"10.1093\/jacamr\/dlab092","article-title":"Extended-spectrum beta-lactamases: an update on their characteristics, epidemiology and detection","volume":"3","author":"Castanheira","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.medine.2026.502443_bib0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.diagmicrobio.2014.07.006","article-title":"Carbapenems and piperacillin\/tazobactam for the treatment of bacteremia caused by extended-spectrum \u03b2-lactamase-producing Proteus mirabilis","volume":"80","author":"Tsai","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0085","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jac\/dkv502","article-title":"Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study","volume":"71","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0090","doi-asserted-by":"crossref","first-page":"e00164","DOI":"10.1128\/AAC.00164-17","article-title":"Efficacy of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae in hematological patients with neutropenia","volume":"61","author":"Gudiol","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0095","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.medine.2026.502443_bib0100","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/antibiotics9020071","article-title":"Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant Enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.medine.2026.502443_bib0115","first-page":"e01699","article-title":"In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/17460913.2025.2468112","article-title":"Cefepime-enmetazobactam: first approved cefepime-\u03b2- lactamase inhibitor combination for multi-drug resistant Enterobacterales","volume":"20","author":"Bhowmick","year":"2025","journal-title":"Future Microbiol"},{"key":"10.1016\/j.medine.2026.502443_bib0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medine.2026.502443_bib0130","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eimc.2022.06.004","article-title":"Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria","volume":"41","author":"Pintado","year":"2023","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"10.1016\/j.medine.2026.502443_bib0135","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 Guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0140","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1128\/AAC.05913-11","article-title":"Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae","volume":"56","author":"Collins","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0145","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0","year":"2025"},{"key":"10.1016\/j.medine.2026.502443_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107115","article-title":"Enterobacterales carrying chromosomal AmpC beta-lactamases in Europe (EuESCPM): epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020\u20132022","volume":"63","author":"Boattini","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medine.2026.502443_bib0155","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/AAC.45.9.2628-2630.2001","article-title":"Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp","volume":"45","author":"Kaye","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0160","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1128\/AAC.01083-07","article-title":"Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use","volume":"52","author":"Choi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0165","first-page":"142","article-title":"Antibiotic treatment of infections caused by AmpC-producing Enterobacterales","volume":"12","author":"Tebano","year":"2024","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.medine.2026.502443_bib0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgar.2021.02.031","article-title":"Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016\u20132018 from USA and Europe: genotypic analysis of beta-lactamases and comparative in vitro activity of cefepime\/enmetazobactam","volume":"25","author":"Belley","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.medine.2026.502443_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106633","article-title":"Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections","volume":"60","author":"Kanj","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medine.2026.502443_bib0180","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1128\/AAC.01420-10","article-title":"Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae","volume":"55","author":"Bulik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0185","doi-asserted-by":"crossref","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0190","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13054-025-05266-1","article-title":"Incidence of hospital-acquired infections due to carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa in critically ill patients in Italy: a multicentre prospective cohort study","volume":"29","author":"De Pascale","year":"2025","journal-title":"Crit Care"},{"key":"10.1016\/j.medine.2026.502443_bib0195","doi-asserted-by":"crossref","first-page":"ofae273","DOI":"10.1093\/ofid\/ofae273","article-title":"Outcomes and predictors of mortality in patients with KPC-Kp infections treated with meropenem vaborbactam: an observational multicenter study","volume":"11","author":"Tumbarello","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0200","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10096-023-04735-1","article-title":"Activity of imipenem\/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa","volume":"43","author":"Delgado-Valverde","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0205","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12890-025-03500-8","article-title":"Activity of aztreonam-avibactam and other beta-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020\u20132022)","volume":"25","author":"Sader","year":"2025","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.medine.2026.502443_bib0210","doi-asserted-by":"crossref","first-page":"dlaf131","DOI":"10.1093\/jacamr\/dlaf131","article-title":"Aztreonam-avibactam for the treatment of serious infections caused by metallo-beta-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE)","volume":"7","author":"Daikos","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.medine.2026.502443_bib0215","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0220","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0225","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to metallo-b-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0230","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/14787210.2024.2397663","article-title":"Efficacy and safety of eravacycline (ERV) in treating infections caused by Gram-negative pathogens: a systematic review and meta-analysis","volume":"22","author":"Chen","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.medine.2026.502443_bib0235","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/jac\/dkaf067","article-title":"In vitro activity of ceftolozane\/tazobactam, ceftazidime\/avibactam and cefiderocol against clinical isolates of non-aeruginosa Pseudomonas","volume":"80","author":"Thene","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.37201\/req\/019.2021","article-title":"Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016\u20132018)","volume":"34","author":"Cant\u00f3n","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.medine.2026.502443_bib0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2025.03.013","article-title":"Emerging resistance mechanisms to newer beta-lactams in Pseudomonas aeruginosa","author":"Oliver","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medine.2026.502443_bib0250","doi-asserted-by":"crossref","first-page":"e02340","DOI":"10.1128\/AAC.02340-18","article-title":"A case-control study of real-life experience with ceftolozane-tazobactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection","volume":"63","author":"Fern\u00e1ndez-Cruz","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0255","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0260","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1093\/jac\/dkae313","article-title":"Comparative evaluation of early treatment with ceftolozane\/tazobactam versus ceftazidime\/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa","volume":"79","author":"Lodise","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0265","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"Hareza","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0270","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S1473-3099(24)00648-0","article-title":"Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study","volume":"25","author":"Shields","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0275","doi-asserted-by":"crossref","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0280","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"Liu","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.medine.2026.502443_bib0285","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.medine.2026.502443_bib0290","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.medine.2026.502443_bib0295","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02712-21","article-title":"In vitro activity of cefiderocol against U.S. and European Gram-negative clinical isolates collected in 2020 as part of the SENTRY Antimicrobial Surveillance Program","volume":"10","author":"Shortridge","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.medine.2026.502443_bib0300","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0305","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/antibiotics13111048","article-title":"Cefiderocol versus best available therapy in the treatment of critically ill patients with severe infections due to resistant Gram-negative bacteria: a systematic review and meta-analysis","volume":"13","author":"Risco-Risco","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.medine.2026.502443_bib0310","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"Suppl 2","key":"10.1016\/j.medine.2026.502443_bib0315","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1093\/cid\/ciad095","article-title":"Durlobactam, a broad-spectrum serine beta-lactamase inhibitor, restores sulbactam activity against Acinetobacter species","volume":"76","author":"Papp-Wallace","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0320","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.3390\/microorganisms10122506","article-title":"Stenotrophomonas maltophilia epidemiology, resistance characteristics, and clinical outcomes: understanding of the recent three years\u2019 trends","volume":"10","author":"Hafiz","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.medine.2026.502443_bib0325","unstructured":"EUCAST Guidance Document on Stenotrophomonas maltophilia Version 2, November 2024. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Guidance_documents\/Stenotrophomonas_maltophilia_guidance_document_v2_20241114.pdf."},{"key":"10.1016\/j.medine.2026.502443_bib0330","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13613-023-01144-7","article-title":"Assessment of the relative benefits of monotherapy and combination therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia pneumonia: a multicenter, observational, real-world study","volume":"13","author":"Chen","year":"2023","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.medine.2026.502443_bib0335","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13054-019-2649-5","article-title":"Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study","volume":"23","author":"Guerci","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.medine.2026.502443_bib0340","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/jac\/dkz116","article-title":"Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia","volume":"74","author":"Shah","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0345","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-019-2627-y","article-title":"Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial","volume":"23","author":"Cisneros","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.medine.2026.502443_bib0350","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s12325-019-00981-y","article-title":"Efficacy and safety of meropenem-vaborbactam versus best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae infections in patients without prior antimicrobial failure: a post hoc analysis","volume":"36","author":"Bassetti","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.medine.2026.502443_bib0355","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jac\/dkac049","article-title":"Impact of ceftazidime\/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)","volume":"77","author":"Cast\u00f3n","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0360","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.medin.2021.12.002","article-title":"The problem of multi-resistance in gram-negative bacilli in intensive care units: treatment and prevention strategies","volume":"46","author":"Garnacho-Montero","year":"2022","journal-title":"Med Intensiva"},{"key":"10.1016\/j.medine.2026.502443_bib0365","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1186\/s12879-024-09700-7","article-title":"Outcomes of inadequate empiric therapy and timing of newer antibacterial therapy in hospitalized adults with culture-positive Enterobacterales and Pseudomonas aeruginosa: a multicenter analysis","volume":"24","author":"Riccobene","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0370","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"Hareza","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251170","article-title":"Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. Huber VC, editor","volume":"16","author":"Musuuza","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.medine.2026.502443_bib0380","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00134-017-4780-6","article-title":"The role of infection models and PK\/PD modelling for optimising care of critically ill patients with severe infections","volume":"43","author":"Tangden","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.medine.2026.502443_bib0385","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.medine.2026.502443_bib0390","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0395","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of beta-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.medine.2026.502443_bib0400","doi-asserted-by":"crossref","first-page":"R84","DOI":"10.1186\/cc12705","article-title":"Meropenem and piperacillin\/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic\/pharmacodynamic target attainment when extended infusions are used?","volume":"17","author":"Carlier","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.medine.2026.502443_bib0405","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"issue":"suppl_2","key":"10.1016\/j.medine.2026.502443_bib0410","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/cid\/cix112","article-title":"Prevention and control of multidrug-resistant Gram-negative bacteria in adult intensive care units: a systematic review and network meta-analysis","volume":"64","author":"Teerawattanapong","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0415","first-page":"73","article-title":"Antimicrobial stewardship programme in critical care medicine: a prospective interventional study","volume":"42","author":"Ruiz","year":"2018","journal-title":"Med Intensiva (Engl Ed)"},{"key":"10.1016\/j.medine.2026.502443_bib0420","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01825-17","article-title":"A before-and-after study of the effectiveness of an antimicrobial stewardship program in critical care","volume":"62","author":"\u00c1lvarez-Lerma","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2026.502443_bib0425","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/cid\/civ1199","article-title":"A systematic review of the definitions determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit","volume":"62","author":"Tabah","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2026.502443_bib0430","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/cid\/cix132","article-title":"The hospital water environment as a reservoir for carbapenem-resistant organisms causing hospital-acquired infections\u2014a systematic review of the literature","volume":"64","author":"Kizny Gordon","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Medicina Intensiva (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572726000986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572726000986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:28:17Z","timestamp":1785576497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173572726000986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2173572726000986"],"URL":"https:\/\/doi.org\/10.1016\/j.medine.2026.502443","relation":{},"ISSN":["2173-5727"],"issn-type":[{"value":"2173-5727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of severe infections by multi-resistant Gram-negative bacteria in critically ill patients","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medine.2026.502443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medin.2026.502443","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Espa\u00f1a, S.L.U. and SEMICYUC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502443"}}